This study evaluated prognosis and the potential role of allogeneic hematopoietic cell transplantation (alloHCT) in patients with high‑risk chronic lymphocytic leukemia (CLL) defined by TP53 abnormalities or a complex karyotype. The investigators compared patients refractory to a single class of targeted agents (single‑refractory high‑risk, SRHR: refractory to either covalent Bruton tyrosine kinase inhibitors cBTKi or B‑cell lymphoma 2 inhibitors BCL2i) with patients refractory to both classes (double‑refractory, DR). The aim was to characterize outcomes in these genetically high‑risk, treatment‑refractory populations and to assess the feasibility and impact of alloHCT in these contexts.
A total of 47 patients were included in the analysis. At study entry, 40 patients had SRHR disease and 7 had DR disease. Over the course of follow‑up, 17 patients who initially met criteria for SRHR progressed to become DR; consequently the overall DR population comprised 24 patients. Within the SRHR group, 78% were cBTKi‑refractory and 22% were BCL2i‑refractory. The data reported are limited to these population counts and categorizations as presented in the abstract.
High‑risk genetic features were common in the SRHR cohort: TP53 abnormalities were present in 90% of SRHR patients. The presence of TP53 alterations or a complex karyotype was the defining high‑risk biology for inclusion in the study population according to the abstract.
Median event‑free survival (EFS), defined in this report as progression on the next line of therapy or death, was 22 months for the SRHR cohort. Overall survival (OS) differed substantially between the groups: median OS was 51 months for patients with SRHR disease and 21 months for patients with DR disease. These findings indicate a markedly poorer prognosis after development of refractoriness to both targeted agent classes.
Twenty‑two patients in the series underwent alloHCT. Outcomes at 2 years after transplantation reported in the abstract were: nonrelapse mortality 19%, relapse incidence 19%, progression‑free survival 62%, and OS 67%. The authors note that long‑term progression‑free survivors were observed following alloHCT, indicating that transplantation can produce durable disease control in a subset of these high‑risk, treatment‑refractory patients.
The abstract describes exploratory comparisons between patients who received alloHCT and those who did not. These exploratory analyses did not show a significant OS benefit in favor of alloHCT in this dataset. The authors therefore state that although transplant is feasible and can yield long‑term progression‑free survivors, its exact survival benefit and optimal timing remain to be determined.
From the reported data, prognosis for patients with high‑risk SRHR CLL is poor but remains better than for patients who progress to DR disease. AlloHCT is feasible in both SRHR and DR settings and may overcome clinical and biological refractoriness for some patients, producing durable remissions. However, based on the reported exploratory analyses, the precise magnitude of benefit from alloHCT, selection criteria for transplant, and optimal timing relative to disease evolution are not resolved by the available data.
The abstract provides patient counts, proportions for refractory status and TP53 abnormality prevalence, median EFS and OS for the reported cohorts, and 2‑year transplant outcome rates. Details not reported in the abstract include specific eligibility criteria, baseline clinical characteristics beyond genetic risk, conditioning regimens, donor types, graft‑versus‑host disease rates, posttransplant management, follow‑up duration distribution, and statistical methods used for comparisons. These methodological and granular outcome details are not available from the abstract and therefore cannot be summarized here.